Liraglutide no light-weight in the fight against diabetes

    loading  Checking for direct PDF access through Ovid

Abstract

The investigational glucagon-like peptide (GLP)-1 analogue liraglutide effectively controls blood glucose levels, without the risk of hypoglycaemia, and reduces bodyweight in patients with type 2 diabetes mellitus (T2DM), according to results from a phase II study presented at the 66th Annual Scientific Sessions of the American Diabetes Association (ADA) [Washington, District of Columbia, US; June 2006]. Liraglutide provided significant reductions in HbA1c levels, compared with placebo, with no major or minor hypoglycaemic episodes; dose-dependent reductions in bodyweight were demonstrated across the liraglutide treatment groups. Late-breaking data from a subgroup analysis showed that, compared with placebo, the two higher doses of liraglutide significantly increased maximal β-cell insulin secretory capacity and first-phase insulin secretion.

Related Topics

    loading  Loading Related Articles